Stoke Therapeutics, Inc. (NASDAQ:STOK) is Skorpios Trust’s Largest Position

Skorpios Trust lowered its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) by 22.5% in the 4th quarter, Holdings Channel.com reports. The fund owned 6,906,181 shares of the company’s stock after selling 2,000,000 shares during the period. Stoke Therapeutics makes up 99.8% of Skorpios Trust’s holdings, making the stock its largest holding. Skorpios Trust owned 0.13% of Stoke Therapeutics worth $76,175,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of STOK. China Universal Asset Management Co. Ltd. purchased a new position in Stoke Therapeutics in the 4th quarter worth approximately $124,000. Intech Investment Management LLC purchased a new position in Stoke Therapeutics in the 3rd quarter worth approximately $160,000. Mesirow Financial Investment Management Inc. purchased a new position in Stoke Therapeutics in the 3rd quarter worth approximately $192,000. Rhumbline Advisers grew its stake in Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock worth $545,000 after buying an additional 2,787 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Stoke Therapeutics by 1,589.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 76,154 shares of the company’s stock worth $936,000 after buying an additional 71,647 shares in the last quarter.

Stoke Therapeutics Stock Performance

Shares of Stoke Therapeutics stock opened at $7.85 on Friday. Stoke Therapeutics, Inc. has a 52-week low of $5.60 and a 52-week high of $17.58. The stock has a market capitalization of $415.79 million, a price-to-earnings ratio of -3.74 and a beta of 0.95. The company has a fifty day moving average of $10.20 and a 200-day moving average of $12.06.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 2,586 shares of the company’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $12.99, for a total transaction of $33,592.14. Following the completion of the sale, the insider now directly owns 44,746 shares in the company, valued at $581,250.54. This represents a 5.46 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, General Counsel Jonathan Allan sold 9,696 shares of the company’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $12.78, for a total transaction of $123,914.88. Following the sale, the general counsel now owns 35,142 shares of the company’s stock, valued at $449,114.76. This represents a 21.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 62,849 shares of company stock worth $809,421 in the last three months. 11.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

STOK has been the subject of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, February 18th. Chardan Capital reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, February 19th. Finally, HC Wainwright upped their price objective on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the company a “buy” rating in a research note on Tuesday, February 18th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Stoke Therapeutics currently has an average rating of “Buy” and a consensus target price of $23.00.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.